RANK expression in EBV positive nasopharyngeal carcinoma metastasis: A ready-to-treat target?

Carlo Resteghini, Salvatore Alfieri, Pasquale Quattrone, Francesca Dominoni, Giovanna Garzone, Ester Orlandi, Laura Locati, Cristiana Bergamini, Donata Galbiati, Nicola Alessandro Iacovelli, Carlo Fallai, Lisa Licitra, Paolo Bossi

Research output: Contribution to journalArticle

Abstract

Epstein Barr Virus (EBV) related Nasopharyngeal Carcinoma (NPC), is an highly chemo- and radiosensitive endemic malignancy in southeast Asia. More than one third of locally advanced cases relapse after curative treatment, especially because of bone, liver and lung metastases. Lymphocyte sub-populations favour EBV-associated carcinogenesis and tumour progression and several strategies aim to reverse this phenomenon. Receptor activator of NF-kB (RANK) and its Ligand (RANKL), key regulator of bone metabolisms, are expressed in several malignancies and tumorinfiltrating Tregs. We collected 17 paired FFPE specimen of primary and metachronous metastatic or regionally relapsed EBV related NPC and evaluated RANK expression by immunohistochemistry. All primary tumour specimens resulted not evaluable whereas all metastatic specimens, regardless of sites, showed high RANK IHC expression in the tumor with no staining in normal surrounding tissues. This observation deserves further clarifications and could open the way to trials testing the hypotesis that targeting the RANK/RANKL pathway with denosumab, an already available, clinically approved monoclonal antibody for metastatic bone lesions, might restore proper antitumor immune response in NPC metastatic patients.

Original languageEnglish
Pages (from-to)96184-96189
Number of pages6
JournalOncotarget
Volume8
Issue number56
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

NF-kappa B
Human Herpesvirus 4
Neoplasm Metastasis
Neoplasms
Bone and Bones
RANK Ligand
Southeastern Asia
Carcinogenesis
Immunohistochemistry
Monoclonal Antibodies
Nasopharyngeal carcinoma
Lymphocytes
Staining and Labeling
Ligands
Recurrence
Lung
Liver
Population

Keywords

  • Denosumab
  • Epstein Barr Virus
  • Nasopharyngeal carcinoma
  • RANK
  • Tregs

ASJC Scopus subject areas

  • Oncology

Cite this

RANK expression in EBV positive nasopharyngeal carcinoma metastasis : A ready-to-treat target? / Resteghini, Carlo; Alfieri, Salvatore; Quattrone, Pasquale; Dominoni, Francesca; Garzone, Giovanna; Orlandi, Ester; Locati, Laura; Bergamini, Cristiana; Galbiati, Donata; Iacovelli, Nicola Alessandro; Fallai, Carlo; Licitra, Lisa; Bossi, Paolo.

In: Oncotarget, Vol. 8, No. 56, 01.01.2017, p. 96184-96189.

Research output: Contribution to journalArticle

@article{9a9e7db7caf64ec697bce7ca049d19c0,
title = "RANK expression in EBV positive nasopharyngeal carcinoma metastasis: A ready-to-treat target?",
abstract = "Epstein Barr Virus (EBV) related Nasopharyngeal Carcinoma (NPC), is an highly chemo- and radiosensitive endemic malignancy in southeast Asia. More than one third of locally advanced cases relapse after curative treatment, especially because of bone, liver and lung metastases. Lymphocyte sub-populations favour EBV-associated carcinogenesis and tumour progression and several strategies aim to reverse this phenomenon. Receptor activator of NF-kB (RANK) and its Ligand (RANKL), key regulator of bone metabolisms, are expressed in several malignancies and tumorinfiltrating Tregs. We collected 17 paired FFPE specimen of primary and metachronous metastatic or regionally relapsed EBV related NPC and evaluated RANK expression by immunohistochemistry. All primary tumour specimens resulted not evaluable whereas all metastatic specimens, regardless of sites, showed high RANK IHC expression in the tumor with no staining in normal surrounding tissues. This observation deserves further clarifications and could open the way to trials testing the hypotesis that targeting the RANK/RANKL pathway with denosumab, an already available, clinically approved monoclonal antibody for metastatic bone lesions, might restore proper antitumor immune response in NPC metastatic patients.",
keywords = "Denosumab, Epstein Barr Virus, Nasopharyngeal carcinoma, RANK, Tregs",
author = "Carlo Resteghini and Salvatore Alfieri and Pasquale Quattrone and Francesca Dominoni and Giovanna Garzone and Ester Orlandi and Laura Locati and Cristiana Bergamini and Donata Galbiati and Iacovelli, {Nicola Alessandro} and Carlo Fallai and Lisa Licitra and Paolo Bossi",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.21856",
language = "English",
volume = "8",
pages = "96184--96189",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "56",

}

TY - JOUR

T1 - RANK expression in EBV positive nasopharyngeal carcinoma metastasis

T2 - A ready-to-treat target?

AU - Resteghini, Carlo

AU - Alfieri, Salvatore

AU - Quattrone, Pasquale

AU - Dominoni, Francesca

AU - Garzone, Giovanna

AU - Orlandi, Ester

AU - Locati, Laura

AU - Bergamini, Cristiana

AU - Galbiati, Donata

AU - Iacovelli, Nicola Alessandro

AU - Fallai, Carlo

AU - Licitra, Lisa

AU - Bossi, Paolo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Epstein Barr Virus (EBV) related Nasopharyngeal Carcinoma (NPC), is an highly chemo- and radiosensitive endemic malignancy in southeast Asia. More than one third of locally advanced cases relapse after curative treatment, especially because of bone, liver and lung metastases. Lymphocyte sub-populations favour EBV-associated carcinogenesis and tumour progression and several strategies aim to reverse this phenomenon. Receptor activator of NF-kB (RANK) and its Ligand (RANKL), key regulator of bone metabolisms, are expressed in several malignancies and tumorinfiltrating Tregs. We collected 17 paired FFPE specimen of primary and metachronous metastatic or regionally relapsed EBV related NPC and evaluated RANK expression by immunohistochemistry. All primary tumour specimens resulted not evaluable whereas all metastatic specimens, regardless of sites, showed high RANK IHC expression in the tumor with no staining in normal surrounding tissues. This observation deserves further clarifications and could open the way to trials testing the hypotesis that targeting the RANK/RANKL pathway with denosumab, an already available, clinically approved monoclonal antibody for metastatic bone lesions, might restore proper antitumor immune response in NPC metastatic patients.

AB - Epstein Barr Virus (EBV) related Nasopharyngeal Carcinoma (NPC), is an highly chemo- and radiosensitive endemic malignancy in southeast Asia. More than one third of locally advanced cases relapse after curative treatment, especially because of bone, liver and lung metastases. Lymphocyte sub-populations favour EBV-associated carcinogenesis and tumour progression and several strategies aim to reverse this phenomenon. Receptor activator of NF-kB (RANK) and its Ligand (RANKL), key regulator of bone metabolisms, are expressed in several malignancies and tumorinfiltrating Tregs. We collected 17 paired FFPE specimen of primary and metachronous metastatic or regionally relapsed EBV related NPC and evaluated RANK expression by immunohistochemistry. All primary tumour specimens resulted not evaluable whereas all metastatic specimens, regardless of sites, showed high RANK IHC expression in the tumor with no staining in normal surrounding tissues. This observation deserves further clarifications and could open the way to trials testing the hypotesis that targeting the RANK/RANKL pathway with denosumab, an already available, clinically approved monoclonal antibody for metastatic bone lesions, might restore proper antitumor immune response in NPC metastatic patients.

KW - Denosumab

KW - Epstein Barr Virus

KW - Nasopharyngeal carcinoma

KW - RANK

KW - Tregs

UR - http://www.scopus.com/inward/record.url?scp=85033387656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033387656&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.21856

DO - 10.18632/oncotarget.21856

M3 - Article

AN - SCOPUS:85033387656

VL - 8

SP - 96184

EP - 96189

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 56

ER -